Highlights from the BSCCP advanced colposcopy training course
Tuesday 6th December 2016
Quality assurance and technological advancements in the detection of cervical abnormalities were some of the highlights from The British Society for Colposcopy and Cervical Pathology (BSCCP) advanced colposcopy training course, held in Birmingham on Thursday 17th November.
Dr Theresa Freeman-Wang introduced the section on new technologies which reflects the growing acceptance by clinicians that technology will be required to help better manage patients within the cervical cancer pathway.
Professor John Tidy, clinical founder of Zilico was invited to present ZedScan, the evidence that supports its claims, and the outcome benefits as seen from centres that have adopted the system.
ZedScan is an innovative diagnostic system that uses Electrical Impedance Spectroscopy (EIS) to detect pre-cancerous abnormalities of the cervix.
Prof Tidy’s presentation considered the difficulties of assessing colposcopic performance and the use of Positive Predictive Vale (PPV) of HG CIN colposcopic impression to confirm HG on biopsy.
It also explored the need for new technologies to reflect new referral groups as a consequence of HPV screening and the post-vaccinated population.
Below are some of the key conclusions from Professor Tidy’s presentation:
- Performance of colposcopy is dependent on the prevalence of disease and will fall as the proportion of women referred with no disease increases
- PPV can be manipulated by under-calling HG lesions, leading to poor sensitivity of HG colposcopic impression due to biopsy on all grade of lesions
- Current practice contributes to a failure to discharge patients with no disease
- HPV primary screening will generate a 66% increase in referral rate over current baseline
- Multiple studies have demonstrated colposcopic performance is influenced by hrHPV genotype
Speaking about ZedScan, Prof Tidy, said: “EIS technology is not affected by acetowhite change and therefore it is independent of HPV genotype. Multiple studies and clinics using ZedScan have highlighted an improved detection of HG CIN, irrespective of the hrHPV genotype. This has led to a confirmed increase in the rate of detection, as well as improved patient centred management because of a more timely diagnosis.”
International evidence has demonstrated that the performance improvements associated with ZedScan are independent of the colposcopy clinic and cytology practice.
As a new technology, ZedScan can therefore help to address many of the current challenges of colposcopy supporting increased use of See & Treat (PPV>90%) and giving colposcopists confidence to discharge patients back to routine screening. (Negative Predictive Value 98.7%).
The event was attended by 60 delegates and Sameer Kothari caught up with a number of KOLs after the presentations. One clinician remarked on the high quality of presentations especially the one on ZedScan and stating that evidence behind the product was overwhelming.
More information about Zilico Ltd
Zilico's product portfolio is centred on its patented Electrical Impedance Spectroscopy (EIS) technology, applicable to a wide range of neoplastic conditions. The company prides itself on creating innovative technology that removes subjectivity, increases accuracy and delivers results in real-time.
Zilico's head office is located in Manchester, UK with a subsidiary office in Sheffield. Manufacturing and R&D functions are also carried out in the UK and Zilico achieved ISO 13485 accreditation in 2013.
For press enquiries, please contact:
Julia Price, tel: +44 7737 864 878; e-mail: email@example.com